Relationship between precorneal retention of viscous eye drops and tear fluid composition

1992 ◽  
Vol 16 (1) ◽  
pp. 23-26 ◽  
Author(s):  
A. Ludwig ◽  
N. J. van Haeringen ◽  
V. M. W. Bodelier ◽  
M. Van Ooteghem
Keyword(s):  
Tear Fluid ◽  
Fluid Composition ◽  
Eye Drops ◽  
Viscous Eye Drops

Fusidic acid in tear fluid: Pharmacokinetic study with fusidic acid viscous eye drops

1987 ◽  
Vol 12 (3) ◽  
pp. 215-218 ◽  
Author(s):  
O. P. Van Bijsterveld ◽  
H. Andriesse ◽  
B. H. Nielsen
Keyword(s):  
Pharmacokinetic Study ◽  
Fusidic Acid ◽  
Tear Fluid ◽  
Eye Drops ◽  
Viscous Eye Drops

Concentration of Fluorescein in Tear Fluid after Instillation as Eye-Drops

1979 ◽  
Vol 11 (2) ◽  
pp. 73-82 ◽  
Author(s):  
H. Barendsen ◽  
J.A. Oosterhuis ◽  
N.J. van Haeringen
Keyword(s):  
Tear Fluid ◽  
Eye Drops

scholarly journals Estimation of lacrimal dysfunction indices in patients with recurrent pterygium

2020 ◽  
Vol 13 (1) ◽  
pp. 11-16
Author(s):  
Erkin N. Bilalov ◽  
Azamat F. Yusupov ◽  
Ahmadjon E. Nozimov ◽  
Okilkhon I. Oripov
Keyword(s):  
Tear Film ◽  
Tear Fluid ◽  
Fluid Composition ◽  
Optimal Correction ◽  
Number Of Patients ◽  
Before And After ◽  
Pathogenetic Therapy ◽  
Recurrent Pterygium ◽  
The Impact ◽  
Tear Dysfunction

The rationale of the research is driven by the severity of dry eye syndrome (DES) in the pterygium recurrencies development as well as by the necessity to investigate tear dysfunction and methods for its optimal correction in this patient population. Purpose of the study. To assess the impact of tear dysfunction indices on the development of recurrent pterygium. Materials and methods. We observed 60 patients (67 eyes) with recurrent pterygium. Patients were divided into four observation groups depending on the number of recurrencies. In order to study the dynamics of the DES manifestations during the postoperative period, pathogenetic therapy was used, which included a tear fluid substitute. All patients underwent a comprehensive assessment of subjective and objective DES indices before and after surgery. Results. A positive dynamics of subjective manifestations and objective indices of DES under the action of a tear substitute after surgery was reliably confirmed. A decrease in the number of patients with type III and IV crystallization after surgery was confirmed. Conclusion. The obtained data indicate an increase in the mucin content in the tear fluid composition, which leads to a stabilization of the tear film and to a decrease in the DES intensity.

scholarly journals Tear Fluid Catecholamines As Biomarkers of the Parkinson’s Disease: A Clinical and Experimental Study

Acta Naturae ◽  
2019 ◽  
Vol 11 (4) ◽  
pp. 99-103 ◽  
Author(s):  
A. R. Kim ◽  
M. R. Nodel ◽  
T. A. Pavlenko ◽  
N. B. Chesnokova ◽  
N. N. Yakhno ◽  
...  
Keyword(s):  
Early Diagnosis ◽  
Clinical Stage ◽  
Tear Fluid ◽  
Fluid Composition ◽  
Stage Model ◽  
Preclinical Stage ◽  
Norepinephrine Concentration ◽  
Important Approach ◽  
Concentration Changes ◽  
Early Clinical Stage

An important approach to an early diagnosis of Parkinsons disease (PD) is screening for peripheral biomarkers in patients at the early clinical stage. In this study, we evaluated catecholamine concentration changes in the tear fluid of untreated PD patients as biomarkers. Norepinephrine and dopamine concentrations in the tear fluid of patients were found to increase compared to those in age controls, which was especially pronounced on the side where motor symptoms appeared. On the contrary, the epinephrine concentration in the tear fluid of patients was reduced bilaterally. Since there was no reason to consider the markers found in the clinical stage of PD as markers of the preclinical stage, we additionally studied the tear fluid composition in mouse neurotoxic models of PD preclinical and clinical stages. The norepinephrine concentration in the tear fluid of mice from the clinical stage model was found to be higher than that in controls; in the preclinical stage model, the norepinephrine concentration had a tendency to increase. Therefore, both PD patients and mice from PD preclinical and clinical stage models manifest unidirectional changes in their tear fluid compositions, which may be considered as promising biomarkers for the development of early diagnosis.

Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease

2020 ◽  
Vol 18 (1) ◽  
pp. 80-97 ◽  
Author(s):  
Jieun Kwon ◽  
Bayasgalan Surenkhuu ◽  
Ilangovan Raju ◽  
Nour Atassi ◽  
Jessica Mun ◽  
...  
Keyword(s):  
Immune Globulin ◽  
Dry Eye ◽  
Therapeutic Potential ◽  
Dry Eye Disease ◽  
Tear Fluid ◽  
Eye Disease ◽  
Eye Drops ◽  
Human Immune ◽  
Citrullinated Protein

Concentration of Fluorescein in Tear Fluid after Instillation as Eye-Drops

1979 ◽  
Vol 11 (2) ◽  
pp. 83-89 ◽  
Author(s):  
H. Barendsen ◽  
J.A. Oosterhuis ◽  
N.J. van Haeringen
Keyword(s):  
Tear Fluid ◽  
Eye Drops

scholarly journals Biopharmaceutics of Topical Ophthalmic Suspensions: Importance of Viscosity and Particle Size in Ocular Absorption of Indomethacin

Pharmaceutics ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 452
Author(s):  
Elisa Toropainen ◽  
Sara Fraser-Miller ◽  
Dunja Novakovic ◽  
Eva M. Del Amo ◽  
Kati-Sisko Vellonen ◽  
...  
Keyword(s):  
Particle Size ◽  
Aqueous Humor ◽  
Tear Fluid ◽  
Eye Drops ◽  
Particle Sizes ◽  
Drug Bioavailability ◽  
Ocular Absorption ◽  
Drug Concentrations ◽  
Biological Tests ◽  
Ocular Pharmacokinetic

Eye drops of poorly soluble drugs are frequently formulated as suspensions. Bioavailability of suspended drug depends on the retention and dissolution of drug particles in the tear fluid, but these factors are still poorly understood. We investigated seven ocular indomethacin suspensions (experimental suspensions with two particle sizes and three viscosities, one commercial suspension) in physical and biological tests. The median particle size (d50) categories of the experimental suspensions were 0.37–1.33 and 3.12–3.50 µm and their viscosity levels were 1.3, 7.0, and 15 mPa·s. Smaller particle size facilitated ocular absorption of indomethacin to the aqueous humor of albino rabbits. In aqueous humor the AUC values of indomethacin suspensions with different particle sizes, but equal viscosity, differed over a 1.5 to 2.3-fold range. Higher viscosity increased ocular absorption 3.4–4.3-fold for the suspensions with similar particle sizes. Overall, the bioavailability range for the suspensions was about 8-fold. Instillation of larger particles resulted in higher tear fluid AUC values of total indomethacin (suspended and dissolved) as compared to application of smaller particles. Despite these tear fluid AUC values of total indomethacin, instillation of the larger particles resulted in smaller AUC levels of indomethacin in the aqueous humor. This suggests that the small particles yielded higher concentrations of dissolved indomethacin in the tear fluid, thereby leading to improved ocular bioavailability. This new conclusion was supported by ocular pharmacokinetic modeling. Both particle size and viscosity have a significant impact on drug concentrations in the tear fluid and ocular drug bioavailability from topical suspensions. Viscosity and particle size are the key players in the complex interplay of drug retention and dissolution in the tear fluid, thereby defining ocular drug absorption and bioequivalence of ocular suspensions.

Sign in / Sign up

Export Citation Format

Share Document